Atara Biotherapeutics (NASDAQ:ATRA) Upgraded at RODMAN&RENSHAW

RODMAN&RENSHAW upgraded shares of Atara Biotherapeutics (NASDAQ:ATRA) to a strong-buy rating in a research note released on Friday morning,Zacks.com reports.

Other research analysts have also issued reports about the stock. Canaccord Genuity Group increased their target price on shares of Atara Biotherapeutics from $13.00 to $21.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Rodman & Renshaw started coverage on Atara Biotherapeutics in a research note on Friday. They issued a “buy” rating and a $25.00 target price for the company. Finally, TD Cowen raised Atara Biotherapeutics to a “strong-buy” rating in a research report on Friday, November 29th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, three have issued a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $18.75.

Atara Biotherapeutics Price Performance

Shares of NASDAQ:ATRA opened at $11.40 on Friday. Atara Biotherapeutics has a 1 year low of $6.50 and a 1 year high of $39.50. The business’s 50-day moving average is $10.80 and its 200-day moving average is $9.54. The company has a market capitalization of $65.66 million, a price-to-earnings ratio of -0.44 and a beta of 0.55.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($2.93) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.77) by $0.84. The business had revenue of $40.19 million during the quarter, compared to analyst estimates of $23.00 million. During the same period last year, the firm posted ($16.50) earnings per share. Analysts anticipate that Atara Biotherapeutics will post -12.12 EPS for the current year.

Hedge Funds Weigh In On Atara Biotherapeutics

Large investors have recently added to or reduced their stakes in the business. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Atara Biotherapeutics in the 2nd quarter valued at $53,000. Cubist Systematic Strategies LLC bought a new stake in shares of Atara Biotherapeutics in the 2nd quarter worth $79,000. State Street Corp raised its holdings in shares of Atara Biotherapeutics by 52.3% in the third quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock valued at $182,000 after purchasing an additional 7,680 shares during the last quarter. FMR LLC lifted its position in shares of Atara Biotherapeutics by 41.7% during the third quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock valued at $204,000 after purchasing an additional 7,381 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in Atara Biotherapeutics by 9.5% during the third quarter. Geode Capital Management LLC now owns 46,720 shares of the biotechnology company’s stock worth $380,000 after purchasing an additional 4,043 shares during the last quarter. Institutional investors own 70.90% of the company’s stock.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.